Laboratory evidence suggests that reduced PDE5 expression triggered by BRAF activation increases the invasiveness and metastatic potential of melanoma cells [2]; hence, pharmacological inhibition of PDE5 might have an unintended effect on melanoma risk. The gene discussed is BRAF; the disease is melanoma.